GSK3B and neoplasm: Study shows that tumor matrix stiffening can activate mammalian target of rapamycin 1 (mTORC1) and achieve cell death resistance under matrix detachment through the integrin-glycogen synthase kinase 3 beta (GSK3β)-FTO-mTOR axis (Zhang et al., 2024).